A Double- Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of BL-8040 Addition to Consolidation Therapy in AML Patients

Trial Profile

A Double- Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of BL-8040 Addition to Consolidation Therapy in AML Patients

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs BL 8040 (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms BLAST
  • Most Recent Events

    • 11 Aug 2017 Status changed from recruiting to discontinued.
    • 10 Jun 2017 Biomarkers information updated
    • 17 Aug 2015 Status changed from not yet recruiting to recruiting according to a BioLineRx media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top